develop
b
cell
immort
method
low
b
cell
number
per
well
use
simultan
b
cell
stimul
b
cell
infect
epsteinbarr
viru
ebv
follow
addit
stimulu
use
method
immunoglobulin
g
igg
produc
immort
b
cell
line
gener
peripher
blood
igg
b
cell
effici
antibodi
alreadi
obtain
cultur
supernat
week
moreov
clonal
analysi
demonstr
monoclon
result
immort
b
cell
line
given
high
immort
effici
monoclon
rate
evid
provid
subclon
necessari
import
applic
b
cell
immort
method
character
autoreact
antibodi
patient
autoimmun
diseas
could
eventu
lead
identif
new
autoantigen
diseas
marker
target
therapi
b
cell
immort
epsteinbarr
viru
ebv
establish
method
antibodi
product
ebv
infect
b
cell
via
receptor
subsequ
transform
continu
divid
lymphoblastoid
cell
line
produc
antibodi
repres
humor
immun
respons
vivo
antibodi
gener
infecti
agent
tumour
cell
render
result
antibodi
attract
therapi
addit
b
cell
immort
valuabl
tool
product
character
autoreact
antibodi
patient
autoimmun
diseas
provid
insight
underli
mechan
humor
immun
respons
autoimmun
lead
identif
new
autoantigen
diseas
marker
target
therapi
major
advantag
b
cell
immort
compar
antibodyproduc
techniqu
gener
fulli
human
antibodi
truli
reflect
specif
divers
human
immun
respons
gener
human
b
cell
repertoir
without
need
specif
immun
origin
b
cell
immort
technolog
first
describ
perform
cultur
b
cell
presenc
ebv
obtain
marmoset
lymphocyt
cell
line
result
immort
b
cell
line
mainli
unstabl
immunoglobulin
igm
produc
clone
low
affin
variou
adjust
procedur
tri
sinc
immort
b
cell
growth
rate
remain
ineffici
recent
antibodi
neutral
sar
coronaviru
cytomegaloviru
cmv
produc
success
introduct
polyclon
b
cell
activ
b
cell
immort
process
b
cell
activ
prior
ebv
infect
respect
hand
method
result
low
reproduc
current
studi
aim
develop
b
cell
immort
procedur
high
effici
reproduc
seed
low
b
cell
number
per
well
could
easili
adopt
product
autoreact
antibodi
patient
autoimmun
diseas
method
especi
advantag
autoreact
b
cell
easili
avail
exampl
cerebrospin
fluid
csf
multipl
sclerosi
ms
patient
synovi
fluid
rheumatoid
arthriti
ra
patient
moreov
seed
low
b
cell
number
per
well
limit
bia
toward
preferenti
outgrowth
fast
grow
immort
b
cell
peripher
blood
healthi
donor
obtain
inform
consent
peripher
blood
mononuclear
cell
pbmc
isol
ficol
hypaqu
densiti
gradient
centrifug
sigmaealdrich
isol
igg
b
cell
pbmc
stain
antibodi
ab
pelabel
antiigg
ab
min
c
subsequ
enrich
mean
fac
sort
use
facsaria
ii
cell
sorter
bd
bioscienc
fac
sort
cell
immedi
use
b
cell
immort
assay
igg
b
cell
cultur
ubottom
plate
nunc
cell
per
well
rpmi
medium
supplement
lglutamin
mm
hepe
buffer
mm
sodium
pyruv
uml
penicillin
mgml
streptomycin
invitrogen
life
technolog
heatinactiv
fetal
bovin
serum
fb
hyclon
immort
experi
start
well
test
condit
isol
b
cell
immort
week
presenc
autolog
irradi
gy
feeder
cell
vv
ebvcontain
supernat
viral
copiesml
cell
line
atcc
mgml
invivogen
fig
next
cell
restimul
day
mgml
togeth
uml
roch
diagnost
cultur
medium
replac
cell
continu
cultur
without
extra
stimuli
immort
verifi
day
seed
screen
cultur
supernat
antibodi
product
use
dot
blot
analysi
light
microscop
examin
cell
growth
paramet
includ
sinc
posit
antibodi
measur
sometim
observ
absenc
b
cell
growth
due
b
cell
activ
start
cultur
cultur
supernat
ml
potenti
immort
b
cell
spot
nitrocellulos
blot
membran
protran
vwr
intern
dri
blot
block
wv
nonfat
dri
milk
nfdm
pb
block
buffer
min
shaker
membran
incub
h
hrplabel
rabbit
antihuman
igg
dako
block
buffer
extens
wash
pb
supplement
vv
triton
antibodi
product
detect
use
deaminobenzidin
dab
substrat
sigmaealdrich
serial
dilut
human
igg
zyme
invitrogen
rang
mgml
immort
phase
cell
restimul
week
mgml
combin
uml
cultur
medium
replac
cultur
continu
without
addit
stimuli
week
immort
statu
verifi
day
cultur
perform
dot
blot
analysi
antibodi
product
light
microscop
examin
cell
growth
mgml
includ
posit
control
cultur
medium
use
neg
control
b
cell
spectratyp
perform
randomli
select
b
cell
line
determin
monoclon
rate
result
immort
b
cell
popul
genom
dna
isol
immort
antibodyproduc
growthposit
b
cell
present
singl
well
variabl
region
b
cell
receptor
heavi
chain
hc
locu
amplifi
ng
dna
use
igh
gene
clonal
assay
invivoscrib
technolog
accord
manufactur
recommend
standard
assay
extens
valid
use
revis
europeanamerican
lymphoma
real
classif
primer
target
conserv
framework
region
fr
use
combin
famlabel
consensu
primer
target
conserv
join
region
j
order
amplifi
variabl
region
genet
rearrang
occur
b
cell
develop
b
cell
receptor
gene
highli
polymorph
subject
divers
mutat
maxim
identif
clonal
rearrang
polymeras
chain
reaction
pcr
perform
fr
use
vh
familyspecif
forward
primer
tabl
analysi
result
fragment
accomplish
use
automat
capillari
electrophoresi
appli
biosystem
polyclon
popul
result
gaussian
distribut
amplif
product
differ
length
monoclon
popul
yield
singl
amplif
product
spectratyp
procedur
detect
clonal
popul
sensit
statist
analys
perform
use
prism
softwar
version
graphpad
analyz
data
use
unpair
student
ttest
p
valu
consid
statist
signific
improv
b
cell
immort
method
develop
fast
gener
iggproduc
b
cell
line
igg
peripher
blood
b
cell
procedur
character
simultan
b
cell
stimul
b
cell
infect
ebv
week
cell
per
well
fig
immort
phase
cell
restimul
day
fac
sort
isol
igg
cell
result
highest
yield
cell
pbmc
puriti
immort
effici
donor
fig
compar
magnet
select
alon
combin
fac
sort
data
shown
igm
immort
b
cell
line
recov
fac
sort
although
sever
igm
well
could
found
magnet
select
consequ
igg
fac
sort
proven
best
choic
igg
b
cell
isol
prior
b
cell
immort
enrich
igg
b
cell
immort
perform
select
iggproduc
immort
b
cell
line
autoantibodi
igg
isotyp
mostli
implic
pathogenesi
autoimmun
diseas
exampl
oligoclon
igg
band
ocb
describ
csf
patient
ms
use
diagnost
indic
sever
autoimmun
diseas
includ
myasthenia
gravi
mg
system
lupu
erythematosu
sle
ra
igg
respons
autoantigen
target
present
therefor
interest
focu
igg
respons
examin
humor
immun
autoimmun
diseas
high
immort
effici
fac
sort
cell
confirm
healthi
donor
donor
fig
consid
individu
immort
experi
immort
effici
could
achiev
fig
variat
cultur
condit
test
togeth
immort
experi
donor
fig
mean
tabl
sequenc
vh
j
genespecif
primer
immort
effici
herebi
obtain
improv
method
indic
mean
percentag
iggand
growthposit
well
fig
variat
concentr
reveal
effici
b
cell
stimul
immort
could
obtain
mgml
without
addit
ebv
infect
data
shown
use
b
cell
stimul
immort
previous
shown
ligand
tolllik
receptor
increas
immort
effici
administ
ebv
infect
caus
polyclon
b
cell
activ
prolifer
studi
reveal
suppress
viral
infect
protect
sever
virus
induc
product
antivir
cytokin
protein
concern
ebv
shown
suppress
initi
lytic
ebv
infect
via
inhibit
lytic
gene
express
connect
howev
never
demonstr
latent
ebv
infect
b
cell
immort
vitro
moreov
shown
posit
effect
b
cell
activ
higher
immort
effici
administ
cell
immort
progress
data
shown
contrast
increas
describ
elicit
b
cell
activ
immort
could
detect
amplif
b
cell
immort
administ
b
cell
immort
phase
data
shown
sinc
receptor
mainli
present
activ
b
cell
like
exert
stimul
effect
b
cell
prolifer
growth
rather
b
cell
activ
also
reflect
higher
immort
effici
combin
restimul
comparison
addit
alon
fig
although
differ
statist
signific
addit
increas
effect
given
express
elev
ebv
infect
stimul
render
immort
cell
even
respons
b
cell
spectratyp
provid
insight
clonal
result
immort
b
cell
use
evalu
need
clone
b
cell
line
monoclon
rate
demonstr
remain
investig
b
cell
line
appear
biclon
fig
preferenti
gener
monoclon
immort
b
cell
line
explain
immort
process
ebvinfect
b
cell
undergo
prolif
crisi
cell
die
apoptosi
surviv
b
cell
becom
activ
eventu
transform
lymphoblastoid
immort
cell
line
consequ
outgrowth
multipl
immort
b
cell
line
rare
start
low
b
cell
number
per
well
nevertheless
high
monoclon
rate
provid
major
advantag
b
cell
immort
method
combin
high
immort
effici
subclon
use
limit
dilut
longer
necessari
consider
reduc
time
span
monoclon
antibodi
produc
improv
b
cell
immort
procedur
could
also
success
perform
total
pbmc
healthi
donor
effici
donor
use
previou
experi
isol
igg
b
cell
howev
largest
proport
result
b
cell
line
appear
igm
immort
b
cell
line
igg
fig
larger
proport
igmproduc
immort
cell
reason
b
cell
peripher
blood
belong
b
cell
popul
b
cell
also
express
ebv
receptor
unpublish
result
activ
produc
larg
amount
igm
moreov
percentag
igm
igg
immort
b
cell
line
produc
total
pbmc
name
resembl
proport
memori
b
cell
present
peripher
blood
signific
differ
could
observ
use
restimul
b
cell
immort
although
trend
toward
higher
percentag
igg
immort
b
cell
observ
stimuli
ad
cultur
compar
singl
stimulu
fig
immort
total
pbmc
ngml
cyclosporin
ad
suppress
growth
cytotox
cell
would
otherwis
target
ebvinfect
b
cell
caus
immort
failur
b
cell
spectratyp
gener
immort
b
cell
line
result
monoclon
b
cell
line
biclon
b
cell
line
fig
emphas
high
monoclon
rate
seed
low
b
cell
number
per
well
use
improv
b
cell
immort
method
success
gener
larg
panel
immort
b
cell
line
peripher
blood
ms
patient
b
cell
line
could
also
recov
csf
ms
patient
preliminari
screen
demonstr
intracellular
bind
antibodi
sever
b
cell
line
human
oligodendroglia
cell
line
suggest
autoreact
addit
autoreact
striat
muscl
protein
shown
immort
b
cell
line
recov
mg
patient
two
exampl
possibl
autoreact
antibodi
produc
patient
autoimmun
diseas
use
b
cell
immort
summari
studi
present
reproduc
b
cell
immort
method
effici
fast
igg
product
igg
peripher
blood
b
cell
simultan
b
cell
stimul
use
b
cell
infect
ebv
follow
addit
stimulu
immort
procedur
addit
use
igm
product
total
pbmc
effici
detail
method
descript
provid
increas
reproduc
b
cell
immort
success
rate
moreov
b
cell
spectratyp
demonstr
monoclon
almost
immort
b
cell
line
origin
isol
igg
b
cell
uniqu
combin
high
immort
effici
high
monoclon
rate
elimin
need
clone
immort
cell
first
time
b
cell
immort
procedur
introduc
high
effici
reproduc
low
b
cell
number
make
immedi
gener
monoclon
antibodi
possibl
